labile
发表于 2025-3-26 21:02:40
http://reply.papertrans.cn/16/1594/159386/159386_31.png
巨头
发表于 2025-3-27 01:47:44
Additivity Failure for Brightnessmary or metastatic carcinoma. This chapter will cover the basic principles of antibodies, subsequent conjugation with bifunctional chelates and radiolabeling for the purpose of radioimmunoimaging or radioimmunotherapy.
有毒
发表于 2025-3-27 07:56:16
http://reply.papertrans.cn/16/1594/159386/159386_33.png
single
发表于 2025-3-27 10:41:34
Encyclopedia of Color Science and Technologyal models to solve these problems, to pave the way for clinical use of MAbs in patients. To illustrate the problems inherent in the development of radiolabeled MAbs for clinical use, we will present our work utilizing MAbs in a variety of brain tumor models.
innate
发表于 2025-3-27 14:11:11
http://reply.papertrans.cn/16/1594/159386/159386_35.png
工作
发表于 2025-3-27 20:32:14
https://doi.org/10.1007/978-3-031-23161-2 large-scale fermentation, the relative ease of their physical and chemical manipulation, and their generally simpler genetic makeup which makes cloning of the enzyme genes potentially easier and more straightforward.
值得
发表于 2025-3-28 01:17:28
Radiolabeled Antibodies: Introduction and Metal Conjugation Techniquesmary or metastatic carcinoma. This chapter will cover the basic principles of antibodies, subsequent conjugation with bifunctional chelates and radiolabeling for the purpose of radioimmunoimaging or radioimmunotherapy.
aristocracy
发表于 2025-3-28 03:08:00
http://reply.papertrans.cn/16/1594/159386/159386_38.png
Colonnade
发表于 2025-3-28 08:45:19
Diagnosis and Therapy of Brain Tumors Utilizing Radiolabeled Monoclonal Antibodiesal models to solve these problems, to pave the way for clinical use of MAbs in patients. To illustrate the problems inherent in the development of radiolabeled MAbs for clinical use, we will present our work utilizing MAbs in a variety of brain tumor models.
使人入神
发表于 2025-3-28 12:31:12
Isolation and Characterization of Natural and Recombinant Cyclophilinsas the binding proteins for the potent immunosuppressant FK-506 and its analogs (52–54). Although Cyp and FKBP are both PPIases, they apparently do not have the same specificity for peptide substrates (16) and Cyp will not bind FK-506 nor will FKBP bind CsA (52, 53).